RIPK2 and cancer: These results indicate that the occurrence, development and clinical prognosis of tumours are not determined by the mutations being spread across the protein, which indicates that there is a lack of recurrent hotspot mutations with the potential of a tumour suppressor pattern, suggesting that RIPK2 may act as a cancer suppressor gene.